SUBSCRIBE
SUBSCRIBE

AstraZeneca

NEWS
Drug Development
Biopharma Update on the Novel Coronavirus: April 30
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 30, 2020.
April 30, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Business
AstraZeneca Collaborates with Oxford’s Jenner Institute on COVID-19 Vaccine
AstraZeneca and the University of Oxford have partnered on the global development and distribution of Oxford’s COVID-19 vaccine it is developing.
April 30, 2020
 · 
3 min read
 · 
Mark Terry
Job Trends
Clinical Catch-Up: April 20-24
Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.
April 24, 2020
 · 
10 min read
 · 
Mark Terry
Drug Development
AstraZeneca and Merck’s Lynparza Improves Survival in Prostate Cancer with Specific Repair Gene Mutations
AstraZeneca and Merck & Co. released more positive data from the Phase III PROfound trial of Lynparza (olaparib) in metastatic castration-resistant prostate cancer.
April 24, 2020
 · 
3 min read
 · 
Mark Terry
Pharm Country
Clinical Catch-Up: April 13-17
There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
April 17, 2020
 · 
11 min read
 · 
Mark Terry
Drug Development
Biopharma Update on the Novel Coronavirus: April 14
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 14, 2020.
April 14, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
BioCapital
Clinical Catch-Up: April 6-10
It was a very busy week for clinical trial news. Here’s a look.
April 10, 2020
 · 
12 min read
 · 
Mark Terry
Courtesy of Alexanderstock23/Shutterstock
Business
AstraZeneca Ramps Up Antibody Research Focused on Treating COVID-19
AstraZeneca made an announcement describing its internal and partnering efforts to battle COVID-19, the disease caused by the novel coronavirus SARS-CoV-2.
April 8, 2020
 · 
3 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: April 8
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 8, 2020.
April 8, 2020
 · 
7 min read
 · 
BioSpace Editorial Staff
Load More
AWARDS
  • 2022 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Press Releases
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
June 18, 2026
 · 
7 min read
Press Releases
AstraZeneca Joins ZERO Prostate Cancer’s Historic ‘Blitz the Barriers’ Initiative as a Founding Partner
June 15, 2026
 · 
3 min read
Press Releases
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
June 14, 2026
 · 
19 min read
Press Releases
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
June 8, 2026
 · 
7 min read
Press Releases
Leica Biosystems Announces Expansion of Collaboration to Scale Precision Medicine and Develop AI-Powered Diagnostics
June 3, 2026
 · 
4 min read
Press Releases
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
June 1, 2026
 · 
7 min read
Press Releases
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
May 29, 2026
 · 
19 min read
Press Releases
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
May 24, 2026
 · 
19 min read
Press Releases
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
May 24, 2026
 · 
19 min read
Press Releases
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
May 22, 2026
 · 
19 min read
Load More